

Title (en)

ANTISENSE OLIGONUCLEOTIDE CHEMOTHERAPY FOR BENIGN HYPERPLASIA OR CANCER OF THE PROSTATE

Title (de)

ANTISENSE-OLIGONUKLEOTID CHEMOTHERAPIE FÜR GUTARTIGE PROSTATAHYPERPLASIA ODER PROSTATAKREBS

Title (fr)

CHIMIOThERAPIE PAR OLIGONUCLEOTIDES ANTISENS DE L'HYPERTROPHIE OU DU CANCER DE LA PROSTATE

Publication

**EP 0851919 A1 19980708 (EN)**

Application

**EP 96935879 A 19960920**

Priority

- US 9615081 W 19960920
- US 401895 P 19950920

Abstract (en)

[origin: WO9711170A1] Methods of selectively inhibiting the growth of or killing prostatic cells, using antisense oligonucleotides to prostate specific genes, are disclosed. The oligonucleotides may have natural nucleic acid structures or may be modified oligonucleotides with enhanced stability or tissue specific targeting. The prostate specific genes to which the antisense may be directed include the AR and the alpha FGF gene. Pharmaceutical compositions including such antisense oligonucleotides are also described for use in the methods. The methods and products are of particular utility in the treatment of benign prostatic hyperplasia or prostate cancer.

IPC 1-7

**C12N 15/11**; **C07H 21/04**; **A61K 31/70**

IPC 8 full level

**C12N 15/113** (2010.01); **A61K 38/00** (2006.01)

CPC (source: EP)

**C12N 15/1136** (2013.01); **C12N 15/1138** (2013.01); **A61K 38/00** (2013.01); **C12N 2310/315** (2013.01); **C12N 2310/351** (2013.01); **C12N 2310/53** (2013.01)

Citation (search report)

See references of WO 9711170A1

Designated contracting state (EPC)

DE FR GB IT

DOCDB simple family (publication)

**WO 9711170 A1 19970327**; AU 7366296 A 19970409; CA 2239976 A1 19970327; EP 0851919 A1 19980708

DOCDB simple family (application)

**US 9615081 W 19960920**; AU 7366296 A 19960920; CA 2239976 A 19960920; EP 96935879 A 19960920